login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VANDA PHARMACEUTICALS INC (VNDA) Stock News
USA
- NASDAQ:VNDA -
US9216591084
-
Common Stock
5.35
USD
+0.95 (+21.59%)
Last: 11/18/2025, 8:00:02 PM
5.37
USD
+0.02 (+0.37%)
Pre-Market:
11/19/2025, 8:44:38 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VNDA Latest News, Press Relases and Analysis
All
Press Releases
18 hours ago - By: Chartmill
- Mentions:
ZYXI
OLMA
ONDS
CPOP
...
Which stocks are moving on Tuesday?
21 hours ago - By: Chartmill
- Mentions:
CMCT
ARVN
ZYXI
OLMA
...
Top movers in Tuesday's session
a day ago - By: Benzinga
- Mentions:
NVO
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients
a day ago - By: Chartmill
- Mentions:
ENR
UUU
GSM
CANF
...
Let's uncover which stocks are experiencing notable gaps during today's session.
2 days ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
21 days ago - By: Chartmill
VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Reports Q3 2025 Earnings Miss on Revenue, Beat on EPS
21 days ago - By: Zacks Investment Research
- Mentions:
VTGN
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates
21 days ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
21 days ago - By: Benzinga
- Mentions:
CGO
ROL
ESRT
NNBR
...
Earnings Scheduled For October 29, 2025
a month ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
a month ago - By: Monumental Sports & Entertainment
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
2 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
2 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"
3 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
3 months ago - By: Stocktwits
Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals”
3 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®
3 months ago - By: Stocktwits
- Mentions:
IWMW
AVUS
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark
3 months ago - By: Vanda Pharmaceuticals Inc.
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder
4 months ago - By: The Motley Fool
Vanda (VNDA) Q2 Revenue Rises 4%
4 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
6 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
6 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
7 months ago - By: Zacks Investment Research
- Mentions:
PRME
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
7 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
7 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026
7 months ago - By: Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
7 months ago - By: Zacks Investment Research
- Mentions:
TARS
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Please enable JavaScript to continue using this application.